ROS1 gene mutation; ROS1 gene fusion; ROS1 gene rearrangement
Jump to navigation
Jump to search
Indications
- evaluation of non-small cell lung cancer (NSCLC)[1][2]
Clinical significance
- ROS1 gene rearrangements in 2% of NSCLC[1]
- lower rates of extrathoracic NSCLC metastases, including fewer brain metastases compared with ALK gene rearrangements
More general terms
Additional terms
- proto-oncogene tyrosine-protein kinase ROS; c-ros protein; p53ros; mcf3 tyrosine kinase receptor; c-ros-1 (ROS1)
- ros proto-oncogene, ros1 proto-oncogene or mcf1 proto-oncogene
References
- ↑ 1.0 1.1 1.2 Pal S. Crizotinib Tx Stakes Claim in ROS1-Positive NSCLC. The TKI boosts outcomes in those with a rare disease -- enough to convince FDA to approve the agent fast and early. MedPage Today. ASCO Reading Room. Feb 9, 2018 https://www.medpagetoday.com/reading-room/asco/lung-cancer/71049
Gainor JF, Tseng D, Yoda S et al Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1-positive non-small cell lung cancer. JCO Precision Oncology. Epub 2017 Aug 16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29333528 Free PMC Article - ↑ 2.0 2.1 ARUP Consult: Lung cancer deprecated reference